Authors
Latest:
Treatment of Patients With HPV Associated Locally Advanced Oropharynx CancerBarbara A. Burtness, MD, professor of medicine, clinical research program leader, Head and Neck Cancers Program, co-director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses the treatment of patients with HPV associated locally advanced oropharynx cancer.
Latest:
Ongoing Trials Studying Immunotherapy as a First-Line Treatment in Head and Neck CancerBarbara Ann Burtness, MD, professor of medicine, Clinical Research Program Leader, Head and Neck Cancers Program and Co-Director, Developmental Therapeutics Research Program at Yale Cancer Center, discusses the ongoing trials looking at immunotherapy as a first-line treatment in head and neck cancer.
Latest:
An Analysis of Ovarian Cancer CareBarbara Ann Goff, MD, discusses an analysis looking at the care of ovarian cancer.
Latest:
Advanced Melanoma Responds Well to Pembrolizumab/Ipilimumab CombinationA regimen of pembrolizumab (Keytruda) and low-dose ipilimumab (Yervoy) was effective, and tolerable, for patients with advanced melanoma, according to results from the phase Ib KEYNOTE-029 clinical trial presented by lead investigator Georgina Long, BSc, PhD, MBBS.
Latest:
Dr. Barbara Burtness on the Psychology of Talking to Patients About Enrolling in Clinical TrialsBurtness says on average, medical professionals should take about 4 minutes or longer to properly explain the clinical trial to their patients, as well as leave ample time for questions at the end of the conversation.
Latest:
Patient-Centered Management of Metastatic Renal Cell CarcinomaThe development of drugs that target angiogenesis and signal transduction pathways in the treatment of metastatic renal cell carcinoma (RCC) has led to improved survival rates for patients.
Latest:
EGFR Mutations in Patients With Lung CancerBarbara J. Gitlitz, MD, associate professor of clinical medicine, Keck Medicine, University of Southern California, discusses EGFR mutations in patients with lung cancer.
Latest:
Insights on Multiple Myeloma From Ola Landgren, MD, PhDIn the treatment of multiple myeloma (MM), following decades of little progress, the last 10 years have been characterized by more clinical advancements than for any other cancer.
Latest:
Minimal Residual Disease (MRD) Marches to Front Line of Myeloma ResearchMore than two dozen abstracts at the December 2013 meeting of the American Society of Hematology (ASH) focused on the detection, measurement, or monitoring of MRD in patients with multiple myeloma.
Latest:
How Oral Targeted Therapies and IV Immunotherapies Disrupted Community Practice FinancingBarbara McAneny, MD, the chief executive officer of New Mexico Cancer Center, discusses how oral targeted therapies and immunotherapies disrupted the traditional methods for financing community practices.
Latest:
Comparison of Cologuard With Other CRC Screening ToolsBarry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses how the Cologuard test compares with other screening tools for colorectal cancer.
Latest:
Overcoming Financial Toxicities of Cancer CareBarry Russo, CEO, The Center for Cancer and Blood Disorders, discusses ways to overcome financial toxicities associated with the cost of cancer care.
Latest:
Mutational Abnormalities in MDSBart L. Scott, MD, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses breakthrough topics in myelodysplastic syndromes (MDS), such as mutational abnormalities.
Latest:
Challenges Impacting Treatment of Cutaneous and Peripheral T-Cell LymphomasBasem William, MD, discusses challenges in treating patients with cutaneous and peripheral T-cell lymphomas, as well as the challenges in conducting clinical trials in this patient population.
Latest:
Choosing Second-Line Therapy for HER2+ Gastric CancerBassel El-Rayes, MD, discusses how he approaches second-line therapy for patients with HER2-positive gastric cancer.
Latest:
CPI-613 in Combination With High Dose ARA-C and MitoxantroneBayard L. Powell, MD, discusses a phase I study that looked at CPI-613 in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).
Latest:
Effects of the Affordable Care ActBen Jones from McKesson Specialty Health discusses how the affordable care act will affect oncologists.
Latest:
Immunotherapy in MelanomaAt the 11th International Congress on Targeted Therapies in Cancer, The International Journal of Targeted Therapies in Cancer spoke with Dr. Sosman about his conference presentation on advances in immunotherapy in melanoma.
Latest:
Future of Immunotherapy in Various Tumor TypesBenjamin G. Neel, MD, faculty, Department of Medicine, Perlmutter Cancer Center, NYU School of Medicine, discusses the future of immunotherapy and how it could play a role in various tumor types.
Latest:
Assessing Recent Progress Toward Cancer Cures at Perlmutter Cancer CenterBenjamin G. Neel, MD, PhD, director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone, discusses how his institution has changed vastly over the last few years, with an increasing number of clinical trials available for patients with lung cancer and other cancers. Clinical trials are often the best option for cancers where the outcomes with conventional treatments may be uncertain, Neel says.
Latest:
Co-Clinical Trial of Olaparib and Temozolomide in SCLC PDX ModelsBenjamin J. Drapkin, MD, PhD, clinical fellow in medicine, Dana-Farber Cancer Institute, resident, Massachusetts General Hospital, discusses the co-clinical trial of olaparib (Lynparza) and temozolomide (temodar) in small cell lung cancer (SCLC) patient-derived xenografts (PDX) models during the 2018 AACR Annual Meeting.
Latest:
Immunotherapy Advances Lung Cancer Treatment LandscapeBenjamin Levy, MD, discusses how the role of immunotherapy has evolved in the treatment landscape of lung cancer and where he sees this research headed in the future.
Latest:
The Global Unmet Need in Breast Cancer CareBenjamin O. Anderson, MD, Seattle Cancer Care Alliance, discusses the current global unmet need for the treatment of patients with breast cancer.
Latest:
Targeted Therapies Show Activity in ROS1 Fusion-Positive Lung CancerBenjamin P. Levy, MD, discusses biomarkers that have led to the development therapies with high response rates in lung cancer.
Latest:
Dr. Benjamin Smith on Complication Burdens in Different Local Treatments for Breast Cancer​Benjamin Smith, MD, discusses a recent study looking at local treatments in breast cancer and the complication burdens associated with them. Smith says that any complications arising in patients with breast cancer within 2 years are strongly associated with their treatments.
Latest:
Targeted Therapies Showing Promise in Colorectal CancerBenjamin Weinberg, MD, discusses novel agents that may impact the treatment landscape for colorectal cancer once made available in the community setting.
Latest:
Sotorasib Shows Early Activity in Advanced Non–Small Cell Lung CancerIn patients with non–small cell lung cancer harboring a KRAS G12C mutation, an aberration without any FDA approved treatment options, a study showed that the investigation agent, sotorasib achieved encouraging antitumor activity.
